Journal of the American Academy of Dermatology · 2016
The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Оценочное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chasset François, Arnaud Laurent, Costedoat-Chalumeau Nathalie, Zahr Noel, Bessis Didier, Francès Camille
Аннотация
BACKGROUND: Up to 30% of patients with cutaneous lupus erythematosus (CLE) fail to respond to hydroxychloroquine (HCQ).
OBJECTIVES: We sought to evaluate the efficacy of increased daily doses of HCQ on cutaneous response in refractory CLE.
METHODS: We conducted an open-label prospective study between 2010 and 2014. Patients with CLE and HCQ blood level less than or equal to 750 ng/mL were included. The daily dose of HCQ was increased to reach blood concentrations greater than 750 ng/mL. The primary end point was the number of responders defined by an improvement of CLE Disease Area and Severity Index score (4 points or 20% decrease) in patients with HCQ blood concentration greater than 750 ng/mL.
RESULTS: We included 34 patients (26 women; median age 45 [range 28-72] years). Two nonadherent patients were excluded. The median CLE Disease Area and Severity Index score before treatment was significantly improved after treatment (8 [range 2-30] vs 1.5 [range 0-30]), P < .001). The primary response criterion was reached in 26 (81%) of the 32 patients analyzed. A decrease in HCQ doses without further CLE flare (median follow-up 15.8 [range 3.06-77.4] months) was achieved in 15 of the 26 responders.
LIMITATIONS: The main limitations of the study are its open-label design and the limited number of patients included.
CONCLUSIONS: Increasing HCQ doses to reach blood concentrations greater than 750 ng/mL should be considered before addition of other treatments in refractory CLE.
OBJECTIVES: We sought to evaluate the efficacy of increased daily doses of HCQ on cutaneous response in refractory CLE.
METHODS: We conducted an open-label prospective study between 2010 and 2014. Patients with CLE and HCQ blood level less than or equal to 750 ng/mL were included. The daily dose of HCQ was increased to reach blood concentrations greater than 750 ng/mL. The primary end point was the number of responders defined by an improvement of CLE Disease Area and Severity Index score (4 points or 20% decrease) in patients with HCQ blood concentration greater than 750 ng/mL.
RESULTS: We included 34 patients (26 women; median age 45 [range 28-72] years). Two nonadherent patients were excluded. The median CLE Disease Area and Severity Index score before treatment was significantly improved after treatment (8 [range 2-30] vs 1.5 [range 0-30]), P < .001). The primary response criterion was reached in 26 (81%) of the 32 patients analyzed. A decrease in HCQ doses without further CLE flare (median follow-up 15.8 [range 3.06-77.4] months) was achieved in 15 of the 26 responders.
LIMITATIONS: The main limitations of the study are its open-label design and the limited number of patients included.
CONCLUSIONS: Increasing HCQ doses to reach blood concentrations greater than 750 ng/mL should be considered before addition of other treatments in refractory CLE.
Предметные рубрики MeSH
Administration, OralAdultAgedAntimalarialsChronic DiseaseDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHydroxychloroquineLupus Erythematosus, CutaneousMaleMaximum Tolerated DoseMiddle AgedPilot ProjectsProspective StudiesRisk AssessmentSeverity of Illness IndexTime FactorsTreatment Outcome